Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis

John P. Fitzgerald; Barbara Ercole; Dipen J. Parekh

doi:10.4103/0970-1591.60448

Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis

John P. Fitzgerald, Barbara Ercole, Dipen J. Parekh

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The basis of treatment for advanced germ cell tumors is chemotherapy and surgical resection of residual disease. Surgery has maintained its role in staging and therapeutic management. Despite these advances, much of the outcomes depend on proper patient selection. Complete removal of all post-chemotherapy residual masses remains the standard of care in the treatment of advanced nonseminomatous germ cell tumors both within and outside of the retroperitoneum.

Original language	English (US)
Pages (from-to)	98-101
Number of pages	4
Journal	Indian Journal of Urology
Volume	26
Issue number	1
DOIs	https://doi.org/10.4103/0970-1591.60448
State	Published - Jan 1 2010
Externally published	Yes

Keywords

Cancer
Testis

ASJC Scopus subject areas

Urology

Access to Document

10.4103/0970-1591.60448

Fingerprint Dive into the research topics of 'Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis'. Together they form a unique fingerprint.

Cite this

@article{484bfa779ca34a9e9771b788b4fcd147,

title = "Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis",

abstract = "The basis of treatment for advanced germ cell tumors is chemotherapy and surgical resection of residual disease. Surgery has maintained its role in staging and therapeutic management. Despite these advances, much of the outcomes depend on proper patient selection. Complete removal of all post-chemotherapy residual masses remains the standard of care in the treatment of advanced nonseminomatous germ cell tumors both within and outside of the retroperitoneum.",

keywords = "Cancer, Testis",

author = "Fitzgerald, {John P.} and Barbara Ercole and Parekh, {Dipen J.}",

year = "2010",

month = jan,

day = "1",

doi = "10.4103/0970-1591.60448",

language = "English (US)",

volume = "26",

pages = "98--101",

journal = "Indian Journal of Urology",

issn = "0970-1591",

publisher = "Medknow Publications and Media Pvt. Ltd",

number = "1",

}

TY - JOUR

T1 - Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis

AU - Fitzgerald, John P.

AU - Ercole, Barbara

AU - Parekh, Dipen J.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The basis of treatment for advanced germ cell tumors is chemotherapy and surgical resection of residual disease. Surgery has maintained its role in staging and therapeutic management. Despite these advances, much of the outcomes depend on proper patient selection. Complete removal of all post-chemotherapy residual masses remains the standard of care in the treatment of advanced nonseminomatous germ cell tumors both within and outside of the retroperitoneum.

AB - The basis of treatment for advanced germ cell tumors is chemotherapy and surgical resection of residual disease. Surgery has maintained its role in staging and therapeutic management. Despite these advances, much of the outcomes depend on proper patient selection. Complete removal of all post-chemotherapy residual masses remains the standard of care in the treatment of advanced nonseminomatous germ cell tumors both within and outside of the retroperitoneum.

KW - Cancer

KW - Testis

UR - http://www.scopus.com/inward/record.url?scp=77950572150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950572150&partnerID=8YFLogxK

U2 - 10.4103/0970-1591.60448

DO - 10.4103/0970-1591.60448

M3 - Article

C2 - 20535294

AN - SCOPUS:77950572150

VL - 26

SP - 98

EP - 101

JO - Indian Journal of Urology

JF - Indian Journal of Urology

SN - 0970-1591

IS - 1

ER -